Tempest Therapeutics, Inc. (TPST)

NCM – Real vaqt narxi. Valyuta: USD

1.92

-0.02 (-1.03%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.94

+0.02 (1.04%)

Bozor oldidan: May 13, 2026, 4:48 AM EDT

06.05.2026

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, Ireland. Updates include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.

29.04.2026

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, May 6-9, 2026. Updates will include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.

22.04.2026

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support initiation of potentially registrational study in Q4 2026 Key manufacturing milestone follows Tempest's recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% complete response in all six efficacy evaluable patients, and accelerated development timeline BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has achieved a key milestone in the development of TPST-2003, Tempest's dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed/refractory multiple myeloma (“rrMM”).

14.04.2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Adds dedicated business development leadership to support Tempest's strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D.

10.04.2026

New Strong Buy Stocks for April 10th

ESCA, GRDN, TPST, ASTE and ECG have been added to the Zacks Rank #1 (Strong Buy) List on April 10th, 2026.

30.03.2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif.

23.03.2026

Tempest Therapeutics Announces Up To $6 Million Private Placement

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 925,927 shares of common stock and short-term series B warrants to purchase up to 925,927 shares of common stock, at a combined purchase price of $2.16 per share of common stock (or $2.159 per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

Tempest Therapeutics, Inc. (TPST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempest Therapeutics, Inc. (TPST)

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

New Strong Buy Stocks for April 10th

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Announces Up To $6 Million Private Placement

Videolar

No Data

Press-relizlar

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

New Strong Buy Stocks for April 10th

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Announces Up To $6 Million Private Placement

Videolar

No Data

Press-relizlar

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Search stocks

Tempest Therapeutics, Inc. (TPST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tempest Therapeutics, Inc. (TPST)

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

New Strong Buy Stocks for April 10th

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Announces Up To $6 Million Private Placement

Videolar

No Data

Press-relizlar

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

New Strong Buy Stocks for April 10th

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Announces Up To $6 Million Private Placement

Videolar

No Data

Press-relizlar

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts